|
 Biocon Biologics has announced that Shreehas P Tambe, deputy CEO of Biocon Biologics, has been appointed as the managing director and CEO of the company from December 5, 2022. He will lead BBL in realizing its goal of being a global biosimilars leader.
Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the board of Biocon Biologics.
Kiran Mazumdar-Shaw, executive chairperson, Biocon & Biocon Biologics, said, “Tambe is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition. His demonstrated track record of business success, deep technical and operational expertise provide him with proven leadership capabilities to assume this role. Shreehas will be aided by a highly experienced executive leadership team in building a future-ready, world leading biosimilars player and a well-recognized global brand that is committed to impact global healthcare.”
“As I step into the role of managing director and CEO, I am deeply humbled and honoured by the confidence that the Board of Biocon Biologics has reposed in me to lead the company. It has been an absolute privilege to have participated in the evolution of Biocon from an enzymes company to a global biopharmaceutical enterprise. As a company we have always pushed boundaries, challenged status-quo, and Dared to Dream - Big! The recent acquisition of Viatris’ global biosimilars business, is a game-changing event in our journey. As a fully integrated Biosimilars company this puts us in a unique position to serve patients across the world. Undoubtedly these are exciting times, and together with an exceptional team, I am looking forward to leading Biocon Biologics in the next phase of growth, said Tambe.
Speaking about Dr Chandavarkar’s contributions, Mazumdar-Shaw said: “I would like to thank Arun for his tremendous contributions to the Biocon Group and Biocon Biologics over the past three decades. Arun has been an integral part of Biocon’s journey since 1990 and came back from retirement to step in as the managing director, Biocon Biologics in January 2021.
Under his leadership, Biocon Biologics has made rapid strides towards realizing its strategic goal of being a global leader in biosimilars. He led the company’s recovery from pandemic-related setbacks and steered the organization back onto the path of sustainable growth. I look forward to his active contributions to the BBL Board, she added.
|